Marinus Pharmaceuticals Inc [MRNS] stock prices are up 6.88% to $1.48 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The MRNS shares have gain 13.46% over the last week, with a monthly amount drifted -83.63%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Marinus Pharmaceuticals Inc [NASDAQ: MRNS] stock has seen the most recent analyst activity on April 16, 2024, when Robert W. Baird downgraded its rating to a Neutral and also revised its price target to $2 from $20. Previously, RBC Capital Mkts downgraded its rating to Sector Perform on April 15, 2024, and dropped its price target to $3. On August 11, 2023, downgrade downgraded it’s rating to Perform and revised its price target to $9 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $23 on January 20, 2023. Truist initiated its recommendation with a Buy and recommended $35 as its price target on September 30, 2020. H.C. Wainwright reiterated a Buy rating for this stock on July 01, 2020, and upped its price target to $9. In a note dated July 01, 2020, Cowen initiated an Outperform rating.
The stock price of Marinus Pharmaceuticals Inc [MRNS] has been fluctuating between $1.11 and $11.26 over the past year. Currently, Wall Street analysts expect the stock to reach $4.67 within the next 12 months. Marinus Pharmaceuticals Inc [NASDAQ: MRNS] shares were valued at $1.48 at the most recent close of the market. An investor can expect a potential return of 215.54% based on the average MRNS price forecast.
Analyzing the MRNS fundamentals
The Marinus Pharmaceuticals Inc [NASDAQ:MRNS] reported sales of 30.99M for trailing twelve months, representing a surge of 0.39%. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -4.24%, Pretax Profit Margin comes in at -4.61%, and Net Profit Margin reading is -4.56%. To continue investigating profitability, this company’s Return on Assets is posted at -0.83, Equity is -2.64 and Total Capital is -1.01. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of6.54.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3833 points at the first support level, and at 1.2917 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.5333, and for the 2nd resistance point, it is at 1.5917.
Marinus Pharmaceuticals Inc [MRNS] reported earnings per share of -$0.74 for its fiscal quarter that ended on 12/31/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.62/share, meaning a difference of $-0.12 and a surprise factor of -19.40%. By comparison, the stated earnings for the previous quarter ended on 9/30/2023 were -$0.61 per share as compared to estimates of -$0.66 per share, a difference of $0.05 representing a surprise of 7.60%.
Ratios To Look Out For
It’s worth pointing out that Marinus Pharmaceuticals Inc [NASDAQ:MRNS]’s Current Ratio is 4.07. In addition, the Quick Ratio stands at 4.01 and the Cash Ratio stands at 2.97. Considering the valuation of this stock, the price to sales ratio is 2.60, the price to book ratio is 4.80.
Transactions by insiders
Recent insider trading involved Shafer Christina, CHIEF COMMERCIAL OFFICER, that happened on Feb 20 ’24 when 2153.0 shares were sold. SVP, GEN. COUNSEL & CORP. SEC., MANNING MARTHA E completed a deal on Feb 20 ’24 to sell 1894.0 shares. Meanwhile, CHAIRMAN AND CEO Braunstein Scott sold 11850.0 shares on Feb 16 ’24.
